Volume Efficacy and Reduced Influence on Measures of Coagulation Using Hydroxyethyl Starch 130/0.4 (6%) with an Optimised in???Vivo???Molecular Weight in Orthopaedic Surgery
- 1 January 2004
- journal article
- clinical trial
- Published by Springer Nature in Drugs in R&D
- Vol. 5 (1) , 1-9
- https://doi.org/10.2165/00126839-200405010-00001
Abstract
Background and objective: Different types of hydroxyethyl starch (HES) affect blood coagulation differently. We studied the effects of HES 130/0.4 on coagulation in major orthopaedic surgery in relation to the pharmacological parameter in vivo molecular weight. Methods: 52 patients were randomly allocated to either HES 130/0.4 (6%, mean molecular weight 130 kDa, molar substitution 0.4) or HES 200/0.5 (6%, control) in a double-blind fashion. Colloidal volume requirements for intra- and postoperative haemodynamic stabilisation were compared. Safety analyses of this pharmacological study included a comparison of coagulation factor tests, in vivo molecular weight, and HES plasma concentrations. Results: The colloidal volumes given were similar at the end of surgery (1602 ± 569 for HES 130/0.4 vs 1635 ± 567mL for HES 200/0.5), 5h later (1958 ± 467 vs 1962 ± 398mL), and up to the first postoperative day (2035 ± 446 vs 2000 ± 424mL). HES in vivo molecular weight at the end of surgery was 88 707 ± 13 938 versus 158 374 ± 33 933Da (p < 0.001) and 5h later was 86 663 ± 16 126 versus 136 299 ± 26 208Da (p < 0.001). In parallel to the lower in vivo molecular weight, factor VIII and von Willebrand factor returned to almost normal in the HES 130/0.4 group up to 5h postoperatively, but not in the control group (p < 0.05). Residual HES plasma concentrations after 24h were low in the HES 130/0.4 group (1.0 mg/mL), but higher in the control group (2.6 mg/mL). Conclusion: HES 130/0.4 and HES 200/0.5 were found to be similar with regard to volume efficacy. Sensitive coagulation parameters returned more rapidly to normal in the HES 130/0.4 group. Lower in vivo molecular weight and more rapid excretion of HES 130/0.4 are the likely explanations for the smaller influence on coagulation in this group.Keywords
This publication has 17 references indexed in Scilit:
- Large-dose Hydroxyethyl Starch 130/0.4 Does Not Increase Blood Loss and Transfusion Requirements in Coronary Artery Bypass Surgery Compared with Hydroxyethyl Starch 200/0.5 at Recommended DosesAnesthesiology, 2003
- Repetitive Large-Dose Infusion of the Novel Hydroxyethyl Starch 130/0.4 in Patients with Severe Head InjuryAnesthesia & Analgesia, 2003
- RETRACTED: Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend®) on measures of coagulationBritish Journal of Anaesthesia, 2002
- Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patientsJournal of Cardiothoracic and Vascular Anesthesia, 2001
- Voluven®, a Lower Substituted Novel Hydroxyethyl Starch (HES 130/0.4), Causes Fewer Effects on Coagulation in Major Orthopedic Surgery than HES 200/0.5Anesthesia & Analgesia, 2001
- The Influence of Intravascular Volume Therapy with a New Hydroxyethyl Starch Preparation (6% HES 130/0.4) on Coagulation in Patients Undergoing Major Abdominal Surgery: RetractedAnesthesia & Analgesia, 2001
- A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgeryCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2000
- Large-Dose Administration of 6% Hydroxyethyl Starch 200/0.5 for Total Hip ArthroplastyAnesthesia & Analgesia, 1996
- HES 200/0.5 Is not HES 200/0.5Thrombosis and Haemostasis, 1995
- Effects of hydroxyethyl starch on blood coagulation, particularly factor VIIITransfusion, 1985